114 related articles for article (PubMed ID: 11041569)
1. Economic analysis of a phase III study of G-CSF vs placebo following allogeneic blood stem cell transplantation.
Stinson TJ; Adams JR; Bishop MR; Kruse S; Tarantolo S; Bennet CL
Bone Marrow Transplant; 2000 Sep; 26(6):663-6. PubMed ID: 11041569
[TBL] [Abstract][Full Text] [Related]
2. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation.
Bence-Bruckler I; Bredeson C; Atkins H; McDiarmid S; Hamelin L; Hopkins H; Perry G; Genest P; Huebsch L
Bone Marrow Transplant; 1998 Nov; 22(10):965-9. PubMed ID: 9849693
[TBL] [Abstract][Full Text] [Related]
3. GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation.
Greenberg P; Advani R; Keating A; Gulati SC; Nimer S; Champlin R; Karanes C; Gorin NC; Powles RL; Smith A; Lamborn K; Cuffie C
Bone Marrow Transplant; 1996 Dec; 18(6):1057-64. PubMed ID: 8971373
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human granulocyte colony-stimulating factor (rh-G-CSF) may accelerate hematopoietic recovery after HLA-identical sibling allogeneic peripheral blood stem cell transplantation.
Ozcan M; Ustün C; Akçağlayan E; Akan H; Arslan O; Ilhan O; Beksaç M; Gürman G; Demirer T; Arat M; Celebi H; Konuk N; Uysal A; Koç H
Bone Marrow Transplant; 2001 Mar; 27(5):499-505. PubMed ID: 11313683
[TBL] [Abstract][Full Text] [Related]
5. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
6. Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study.
Joshi SS; Bishop MR; Lynch JC; Tarantolo SR; Abhyankar S; Bierman PJ; Vose JM; Geller RB; McGuirk J; Foran J; Bociek RG; Hadi A; Day SD; Armitage JO; Kessinger A; Pavletic ZS
Cytotherapy; 2003; 5(6):542-52. PubMed ID: 14660050
[TBL] [Abstract][Full Text] [Related]
7. [A pilot study of G-CSF mobilized allogeneic bone marrow cells plus peripheral blood stem cells transplantation for malignant hematological diseases].
Chen Y; Huang X; Xu L; Liu D; Zhang Y; Ren H; Guo N; Lu D
Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(19):1306-9. PubMed ID: 12509932
[TBL] [Abstract][Full Text] [Related]
8. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
9. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.
Zumberg MS; Leather HL; Nejame C; Meyer C; Wingard JR
Cytotherapy; 2002; 4(6):531-8. PubMed ID: 12568989
[TBL] [Abstract][Full Text] [Related]
10. Hematopoietic growth factor after autologous peripheral blood transplantation: comparison of G-CSF and GM-CSF.
Jansen J; Thompson EM; Hanks S; Greenspan AR; Thompson JM; Dugan MJ; Akard LP
Bone Marrow Transplant; 1999 Jun; 23(12):1251-6. PubMed ID: 10414911
[TBL] [Abstract][Full Text] [Related]
11. G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs.
Tarella C; Castellino C; Locatelli F; Caracciolo D; Corradini P; Falda M; Novarino A; Tassi V; Pileri A
Bone Marrow Transplant; 1998 Feb; 21(4):401-7. PubMed ID: 9509976
[TBL] [Abstract][Full Text] [Related]
12. Early vs delayed administration of G-CSF following autologous peripheral blood stem cell transplantation.
Colby C; McAfee SL; Finkelstein DM; Spitzer TR
Bone Marrow Transplant; 1998 May; 21(10):1005-10. PubMed ID: 9632273
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF.
Hill GR; Morris ES; Fuery M; Hutchins C; Butler J; Grigg A; Roberts A; Bradstock K; Szer J; Kennedy G; Morton J; Durrant S
Biol Blood Marrow Transplant; 2006 Jun; 12(6):603-7. PubMed ID: 16737933
[TBL] [Abstract][Full Text] [Related]
14. Economic impact of palifermin on the costs of hospitalization for autologous hematopoietic stem-cell transplant: analysis of phase 3 trial results.
Elting LS; Shih YC; Stiff PJ; Bensinger W; Cantor SB; Cooksley C; Spielberger R; Emmanoulides C
Biol Blood Marrow Transplant; 2007 Jul; 13(7):806-13. PubMed ID: 17580258
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte-colony-stimulating factor-mobilized prophylactic granulocyte transfusions given after allogeneic peripheral blood progenitor cell transplantation result in a modest reduction of febrile days and intravenous antibiotic usage.
Oza A; Hallemeier C; Goodnough L; Khoury H; Shenoy S; Devine S; Augustin K; Vij R; Trinkaus K; Dipersio JF; Adkins D
Transfusion; 2006 Jan; 46(1):14-23. PubMed ID: 16398726
[TBL] [Abstract][Full Text] [Related]
16. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV.
Remberger M; Naseh N; Aschan J; Barkholt L; LeBlanc K; Svennberg P; Ringdén O
Bone Marrow Transplant; 2003 Jul; 32(2):217-23. PubMed ID: 12838288
[TBL] [Abstract][Full Text] [Related]
17. Delaying treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for hematological malignancies: a prospective randomized trial.
Ciernik IF; Schanz U; Gmür J
Bone Marrow Transplant; 1999 Jul; 24(2):147-51. PubMed ID: 10455342
[TBL] [Abstract][Full Text] [Related]
18. A randomized, multicenter study of G-CSF starting on day +1 vs day +5 after autologous peripheral blood progenitor cell transplantation.
de Azevedo AM; Nucci M; Maiolino A; Vigorito AC; Simões BP; Aranha FJ; Tabak DG; Voltarelli J; de Souza CA
Bone Marrow Transplant; 2002 May; 29(9):745-51. PubMed ID: 12040471
[TBL] [Abstract][Full Text] [Related]
19. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
20. Evidence that donor intrinsic response to G-CSF is the best predictor of acute graft-vs-host disease following allogeneic peripheral blood stem cell transplantation.
Dhédin N; Chamakhi I; Perreault C; Roy DC; Sauvageau G; Ducruet T; Busque L; Fish D; Bélanger R; Roy J
Exp Hematol; 2006 Jan; 34(1):107-14. PubMed ID: 16413397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
